22:10 , Oct 15, 2018 |  BC Extra  |  Politics & Policy

FDA guides on minimal residual disease endpoint in hematologic cancer trials

FDA Commissioner Scott Gottlieb highlighted minimal residual disease (MRD)'s potential as a surrogate endpoint in clinical trials when he unveiled FDA's draft guidance on using MRD in hematologic malignancy drug development in a statement Monday....
19:29 , Oct 5, 2018 |  BC Week In Review  |  Clinical News

FDA approves minimal residual disease diagnostic

FDA approved clonoSEQ Assay from Adaptive Biotechnologies Corp. (Seattle, Wash.) to detect minimal residual disease (MRD) in patients with acute lymphoblastic leukemia (ALL) or multiple myeloma (MM). The agency said clonoSEQ Assay is the first...
22:39 , Sep 28, 2018 |  BC Extra  |  Company News

FDA approves minimal residual disease diagnostic

FDA approved clonoSEQ Assay from Adaptive Biotechnologies Corp. (Seattle, Wash.) to detect minimal residual disease (MRD) in patients with acute lymphoblastic leukemia (ALL) or multiple myeloma (MM). The agency said clonoSEQ Assay is the first...
18:15 , Sep 7, 2018 |  BC Week In Review  |  Company News

Driver launches with cancer trial matching app

Driver Inc. debuted with a platform to match patients to clinical trials based on tumor and saliva samples and medical records. The company’s app presents customers with clinical trials for which they are eligible at...
20:15 , Sep 6, 2018 |  BC Extra  |  Company News

Driver launches with cancer trial matching app

Driver Inc. debuted with a platform to match patients to clinical trials based on tumor and saliva samples and medical records. The company’s app presents customers with clinical trials for which they are eligible at...
22:48 , Jan 5, 2018 |  BC Week In Review  |  Company News

Adaptive, Microsoft to develop universal TCR-antigen map

Adaptive Biotechnologies Corp. (Seattle, Wash.) and Microsoft Corp.(NASDAQ:MSFT) partnered to develop a universal map of T cell receptors (TCRs) and their antigens using Adaptive's immunosequencing platform and Microsoft's research, machine-learning and cloud computing technologies. The...
00:20 , Jan 5, 2018 |  BC Extra  |  Company News

Adaptive, Microsoft to develop universal TCR-antigen map

Adaptive Biotechnologies Corp. (Seattle, Wash.) and Microsoft Corp.(NASDAQ:MSFT) partnered to develop a universal map of T cell receptors (TCRs) and their antigens using Adaptive's immunosequencing platform and Microsoft's research, machine-learning and cloud computing technologies. The...
23:46 , Sep 19, 2017 |  BC Extra  |  Company News

Management tracks: OncoMed, Vividion, Spero

Cancer company OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) said Chairman and CEO Paul Hastings began a medical leave of absence. Proteomics company Vividion Therapeutics Inc. (San Diego, Calif.) named Diego Miralles CEO. He was president of the...
19:56 , May 24, 2017 |  BC Innovations  |  Translation in Brief

Unusual suspects

While viral proteins have been considered prime targets for immunotherapy in cancers triggered by viral infections, an NCI study indicates mutated host antigens could be equally or more immunogenic. The study, published in...
16:07 , Mar 28, 2017 |  BC Innovations  |  Translation in Brief

Minority power

A...